Home / Resources / Early Clinical resources

早期临床

最新资源

PBPK Modeling in Lieu of Clinical Endpoint Bioequivalence Study for Generic Tazarotene Cream 0.05%

PBPK Modeling in Lieu of Clinical Endpoint Bioequivalence Study for Generic Tazarotene Cream 0.05%

5 Key Principles of Modern PK/PD in 2026

5 Key Principles of Modern PK/PD in 2026

Mechanistic Surface pH Modelling Improves PBPK Prediction of a Weakly Acidic Drug: Case Study of Bempedoic Acid

Mechanistic Surface pH Modelling Improves PBPK Prediction of a Weakly Acidic Drug: Case Study of Bempedoic Acid

Dermal PBPK Modelling of Propylparaben with a Novel Skin Metabolism Framework

Dermal PBPK Modelling of Propylparaben with a Novel Skin Metabolism Framework

精选资源

Dermal PBPK Modelling of Propylparaben with a Novel Skin Metabolism Framework

Dermal PBPK Modelling of Propylparaben with a Novel Skin Metabolism Framework

Upcoming early clinical webinars

网络研讨会

Explore Smarter, Faster PK/PD with Phoenix

2026 年 7 月 7 日 – 10-11 AM ET/CET/JST

网络研讨会

Building IND-Ready and Investor-Ready Development Programs

2026 年 7 月 9 日 – 10:00 - 11:00am ET

网络研讨会

The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors

2026 年 7 月 16 日 – 3:00- 4:00 pm, JST

Latest early clinical blogs

All Early clinical - Blog

药物开发中 PK/PD 建模的机器学习

美国 FDA MIDD 配对试点计划如何帮助赞助商

揭秘临床 DDI 研究：精准测量代谢产物

为何 FDA 批准 omaveloxolone 用于治疗弗里德赖希共济失调症意义重大

细胞疗法开发的主要考虑因素

降低药物开发风险：早期开发中的关键化学、制造和控制（CMC）及基于生理的药代动力学（PBPK）方法

在以下活动中与我们的专家会面

Simcyp 专题研讨会：DDI（复杂药物相互作用的预测与评估）日本

2026 年 8 月 3 - 4 日

Simcyp 线下研讨会：PBPK 建模在生物药剂学中的应用 — 日本

2026 年 8 月 5 - 6 日

Arena Clinical Data Management 2026

2026 年 9 月 9 - 10 日

All early clinical resources

How does Pinnacle 21 Enterprise differ from the Community version?

Certara Products - Pinnacle 21, Blog

ADC 首次人体（FIH）剂量选择：成功设计 FIH 研究的关键

ADC, Biologics, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, Blog

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Certara Services, Clinical Pharmacology, Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Conference

Formulate Faster: A Purpose-Built Toolkit for Bioequivalence (Phoenix IVIVC Toolkit)

Certara Products - Phoenix, Clinical Pharmacology, Modeling and Simulation - PK/PD, On-Demand Webinar

Marbach DDI Workshop 2026

Certara Products - Simcyp, Drug-Drug Interactions (DDI), Modeling and Simulation - PBPK, Conference

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Rare and Neglected Diseases, Blog

Metatdata as Infrastructure: Designing for Reuse, Insight, and Auditability

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, On-Demand Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Start right, finish strong: 抗体-药物偶联物（ADC）研究成功之道

ADC, Biologics, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - QSP, On-Demand Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Alternative parameters in NCA using Phoenix WinNonlin

Certara Products - Phoenix, Modeling and Simulation - PK/PD, On-Demand Webinar

‹
1
……
5
6
7
8
9
……
69
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software